| Date | Title | | | 05/17/12 | StemCells, Inc. Reports Positive Interim Safety Data From Spinal Cord Injury Trial| Trial Proceeding to Enroll Patients With Incomplete Injury
NEWARK, Calif., May 17, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced completion of the first planned interim safety review of the Company's Phase I/II spinal cord injury clinical trial, which indicated that the surgery, immunosuppression and the cell transplants have been well-tolerated. The trial, which is designed to evaluate the safety and preliminary efficacy of the Company's proprietary HuCNS-SC® cells (pu... |
|  | | 05/10/12 | StemCells, Inc. Reports First Quarter 2012 Financial Results and Provides Business Update| NEWARK, Calif., May 10, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the first quarter ended March 31, 2012 and provided a business update.
"The first quarter of 2012 turned out to be pivotal in the Company's pursuit of cell-based therapeutics for a broad array of CNS disorders," said Martin McG... |
| | | 05/09/12 | StemCells, Inc. to Provide Progress Report on Spinal Cord Injury Trial at the Interdependence 2012 Global SCI Conference Co-Sponsored by the Rick Hansen Institute and the Rick Hansen Foundation| NEWARK, Calif., May 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that Armin Curt, MD, FRCPC, Professor and Chairman, Spinal Cord Injury Center at the University of Zurich, and Medical Director of the Paraplegic Center at the Balgrist University Hospital and principal investigator for the Company's Phase I/II clinical trial in chronic spinal cord injury, will provide a progress report on the trial on Thursday, May 17 at the Interdependence 2012 Global SCI Conference. ... |
| | | 05/07/12 | StemCells, Inc. Announces Webcast to Discuss First Quarter 2012 Financial Results and Business Update| NEWARK, Calif., May 7, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter ended March 31, 2012 after the market close on Thursday, May 10. In connection with this announcement, StemCells will host a conference call and webcast to discuss its results and an update... |
| | | 04/02/12 | StemCells, Inc's Milestone Clinical Trial in Pelizaeus-Merzbacher Disease Shows Evidence of Myelination Following Human Neural Stem Cell Transplantation|
Trial Provides Proof-of-Concept for Cell-Based Therapy in a Myelination Disorder
Company to Host Conference Call Today to Discuss Summary Results
NEWARK, Calif., April 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced preliminary evidence of progressive and durable donor-cell derived myelination in all four patients who underwent transplantation with the Company's proprietary HuCNS-SC® cells (purified human neural stem cells) in its clinical trial for Pelizaeus... |
| | | 03/30/12 | StemCells, Inc. Announces Webcast to Discuss Pelizaeus-Merzbacher Disease Clinical Trial Results| NEWARK, Calif., March 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it will host a conference call and webcast to discuss results from its Phase I clinical trial in Pelizaeus-Merzbacher Disease (PMD) on Monday, April 2, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time). A summary of the trial results will be presented on Saturday, March 31, at the 2012 European Leukodystrophy Association (ELA) Families/Scientists Meeting in Paris. The Phase I trial was complet... |
| | | 03/20/12 | StemCells, Inc. Grants genOway Exclusive License to Gene Insertion Technology for Genetically Engineered Mice| genOway to be Exclusive Source Worldwide for This Cell Manipulation Technology in Genetically Modified Mice
NEWARK, Calif., March 20, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) and genOway (NYSE:ALGEN) announced today that they have entered into a license agreement under which StemCells has granted genOway a worldwide, exclusive license to StemCells' Internal Ribosome Entry Site (IRES) technology for use in the development and commercialization of genetically engineered mice. Financ... |
| | | 03/13/12 | StemCells, Inc. Reports Fourth Quarter and Year End 2011 Financial Results and Provides Business Update|
.yom-art-content .gnwlistitemmarginbottom {
MARGIN-BOTTOM: 10px
}
.yom-art-content .gnwtablebottommargin {
MARGIN-BOTTOM: 10px
}
.yom-art-content .gnwcellpaddingleft0 {
PADDING-LEFT: 0px
}
.yom-art-content .gnwverticalaligntop {
VERTICAL-ALIGN: top
}
.yom-art-content .gnwtextaligncenter {
TEXT-ALIGN: center
}
.yom-art-content .gnwcellparagraphmargin {
MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px
}
.yom-art-content .gnwverticalalignbottom {
VERTICAL-ALIGN: bottom
}
.yom-art-c... |
| | | 03/09/12 | StemCells, Inc. Announces Webcast to Discuss 2011 Financial Results and Business Update| NEWARK, Calif., March 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and year ended December 31, 2011 after the market close on Tuesday, March 13. In connection with this announcement, StemCells will host a conference call and webcast to discuss its resul... |
| | | 03/08/12 | StemCells, Inc. to Present at the 24th Annual Roth Growth OC Conference| NEWARK, Calif., March 8, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Rodney Young, Chief Financial Officer, will present an update on the Company's programs and operations at the 24th Annual Roth OC Growth Stock Conference on Wednesday, March 14th at 8:30 a.m. Pacific Time in Laguna Niguel, California.
Additionally, the Company will be hosting one-on-one meetings throughout the day. Institutional investors that would like to request a meeting should contact Ro... |
| | | 02/27/12 | StemCells, Inc. to Participate in Qatar International Conference on Stem Cell Science and Policy 2012| NEWARK, Calif., Feb. 27, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it will participate in the Qatar International Conference on Stem Cell Science and Policy, which is being held in Qatar from February 27 to March 1, 2012. The Company, which is the leader in development of cell-based therapeutics for central nervous system disorders, was specifically invited by the conference's sponsors, the State of Qatar and Amir of Qatar His Highness Sheikh Hamad bin Khalifa A... |
| | | 02/08/12 | StemCells, Inc. to Present at 2012 BIO CEO Investor Conference| NEWARK, Calif., Feb. 8, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will present an update on the Company's programs and operations at the 14th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference to be held February 13-14 in New York City. Mr. McGlynn is scheduled to speak at 11:00 a.m. Eastern Time on Tuesday, February 14.
A live webcast of the presentation will be available through the Company's corpor... |
| | | 02/02/12 | StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial| NEWARK, Calif., Feb. 2, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD), the most common form of AMD. AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30 million peopl... |
| | | 01/30/12 | StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision| NEWARK, Calif., Jan. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the publication of preclinical data demonstrating that its proprietary HuCNS-SC® cells (purified human neural stem cells) protect host photoreceptors and preserve vision in an animal model of retinal disease. The preclinical results are highly relevant to human disorders of vision loss, the most notable of which is dry age-related macular degeneration (AMD). The study is available online at http:... |
| | | 01/09/12 | StemCells, Inc. to Present at Biotech Showcase 2012| NEWARK, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that Martin McGlynn, President and CEO, will present a business update at the Biotech Showcase 2012 to be held January 9-11 at the Parc 55 Wyndham Hotel in San Francisco, California. Mr. McGlynn is scheduled to speak on Tuesday, January 10, at 1:45 ... |
| |
|
